Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).

Cai, Chun

Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198). [electronic resource] - The Journal of pharmacology and experimental therapeutics Oct 2010 - 223-30 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

1521-0103

10.1124/jpet.110.167965 doi


AMP-Activated Protein Kinase Kinases
Animals
Antibiotics, Antineoplastic--antagonists & inhibitors
Blotting, Western
Calcium--pharmacology
Cardiomyopathies--chemically induced
Cardiotonic Agents--pharmacology
Doxorubicin--analogs & derivatives
Electrophoresis, Polyacrylamide Gel
Indicators and Reagents
Male
Mass Spectrometry
Myocytes, Cardiac--drug effects
Nitric Oxide Synthase Type II--biosynthesis
Phosphorylation
Poly Adenosine Diphosphate Ribose--pharmacology
Protein Kinase C-epsilon--antagonists & inhibitors
Protein Kinases--metabolism
Rats
Rats, Wistar